XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-based Compensation
12 Months Ended
Dec. 31, 2021
Share-based Payment Arrangement [Abstract]  
Stock-based Compensation
NOTE 11 - STOCK-BASED COMPENSATION:
In September 2021, the Company adopted the “Valens Semiconductor Ltd. 2021 Share Incentive Plan”.
The Company’s stock options and Restricted Stock Units (RSUs) have a term of up to 10 years from grant date unless extended by the Board of Directors. Options and RSUs generally vest as follows: 25% on the first anniversary from the “Vesting Start Date” as defined in the grant agreement and remainder vest ratably over the following 12 quarters.
During 2021, the Company added 8,370,000 Ordinary Shares to the Ordinary Shares pool reserved for issuance (2,318,860 in 2020). As of December 31, 2021, and 2020, the number of ordinary shares included in the Company’s stock incentive plans totaled to 28,383,788 and 20,013,788, respectively.
Stock Options
On September 30, 2021 the vesting of 814,272 options of one of the Company’s executives were accelerated. The Company expensed $3,396 thousand in the general and administrative expenses due to such vesting acceleration.
 
The following is a summary of the status of the Company’s share option plan as of December 31, 2021, as well as changes during the years:
 
    
December 31, 2021
 
    
Number of
Options
    
Weighted-
Average
Exercise price
 
Options outstanding at the beginning of the year
     15,955,892      $ 0.71  
Granted during the year
     1,662,897      $ 0.90  
Exercised during the year
     (1,722,880    $ 0.72  
Forfeited during the year
     (446,396    $ 0.84  
    
 
 
          
Outstanding at the end of the year
     15,449,513      $ 0.73  
    
 
 
          
Options exercisable at
year-end
     11,449,733      $ 0.68  
    
 
 
          
The following table summarizes information about share options outstanding as of December 31, 2021:
 
Outstanding as of December 31, 2021
    
Exercisable as of December 31, 2021
 
Range of
exercise
prices
  
Number
outstanding
    
Weighted
average
remaining
contractual
term
    
Weighted
average
exercise
price
    
Aggregate
intrinsic value
(U.S. dollars
in thousands)
    
Number
Exercisable
    
Weighted
average
remaining
contractual
term
    
Weighted
Average
exercise
price
    
Aggregate
intrinsic
value (U.S.
dollars in
thousands)
 
$0.15-$0.86
     15,403,350        6.12      $ 0.72        107,517        11,416,017        5.29      $ 0.67        80,243  
$1.87      5,963        9.03      $ 1.87        35        —          —          —          —    
$2.10      33,126        2.69      $ 2.10        186        33,126        2.69      $ 2.10        186  
$9.07      7,074        9.95      $ 9.07        —          590        9.95      $ 9.07        —    
The following assumptions were used for options granted during the year in order to estimate the fair value of stock-based compensation awards:
 
    
2021
   
2020
 
Expected term
    
6-10
     
6-10
 
Expected volatility
    
46.71%-50.7%
      48.15
Expected dividend rate
     0     0
Risk-free rate
    
0.61%-1.74
   
0.42%-1.69
During 2021, 2020 and 2019, 321,777, 3,347,705 and 1,003,185 options respectively, were granted to several related parties (please refer to Note 16 regarding Related Parties).
As of December 31, 2021, the unrecognized compensation costs related to unvested stock options totaled to $13,853 thousand, which are expected to be expensed over a weighted-average period of 2.7 years.
2,300,980 out of the outstanding options that have not yet vested as of December 31, 2021, have acceleration mechanisms according to certain terms set forth in the grant agreements primarily in the case of a M&A Transaction which constitutes a Liquidation Event (as defined in Note 9).
The unrecognized compensation costs related to those unvested stock options are $7,281 thousand, which are expected to be recognized over a weighted-average period of 2.3 years.
 
The following table presents the classification of the stock options expenses for the periods indicated:
 
    
Year Ended December 31
 
    
2021
    
2020
    
2019
 
    
 
 
    
 
 
    
 
 
 
    
U.S. dollars in thousands
 
Cost of revenue
     158        178        180  
Research and development
     1,684        1,267        1,266  
Selling, general and administrative
     7,981        3,884        1,418  
    
 
 
    
 
 
    
 
 
 
Total stock-based compensation -Stock Options
  
 
9,823
 
  
 
5,329
 
  
 
2,864
 
    
 
 
    
 
 
    
 
 
 
Restricted Stock Units
The following is a summary of the status of the Company’s RSU’s as of December 31, 2021, as well as changes during the year:
 
    
December 31, 2021
    
Number of
RSUs
    
Weighted-
Average Grant
Date Fair Value
RSUs outstanding at the beginning of the year
     —        —  
Granted during the year
     133,384      $7.89
Exercised during the year
     —        —  
Forfeited during the year
     —        —  
    
 
 
      
Outstanding at the end of the year
     133,384      $7.89
    
 
 
      
RSUs exercisable at
year-end
     616      $7.89
    
 
 
      
 
Outstanding as of December 31, 2021
    
Exercisable as of December 31, 2021
 
Range of
exercise
prices
    
Number
outstanding
    
Weighted
average
remaining
contractual
term
    
Weighted
average
exercise
price
    
Aggregate
intrinsic value
(U.S. dollars
in thousands)
    
Number
Exercisable
    
Weighted
average
remaining
contractual
term
    
Weighted
Average
exercise
price
    
Aggregate
intrinsic
value (U.S.
dollars in
thousands)
 
$ 7.89        133,384        9.96      $ 7.89      $ 76        616        9.96      $ 7.89        ( *) 
(*)   Less than $1 thousand
As of December 31, 2021, the unrecognized compensation cost related to unvested RSUs totaled to approximately $914 thousand and is expected to be expensed over a weighted-average recognition period of approximately 3.8 years.
During 2021, 2020 and 2019, 7,398, 0 and 0 RSU’s respectively, were granted to several related parties (please refer to Note 17 regarding Related Parties).
The following table presents the classification of RSU’s expenses for the periods indicated:
 
    
Year Ended December 31
 
    
2021
    
2020
    
2019
 
    
 
 
    
 
 
    
 
 
 
    
U.S. dollars in thousands
 
Cost of revenue
     6        —          —    
Research and development
     22        —          —    
Selling, general and administrative
     18        —          —    
    
 
 
    
 
 
    
 
 
 
Total stock-based compensation-RSUs
  
 
46
 
  
 
—  
 
  
 
—